Paralax Life Sciences invests own capital in technologies and products for the life science and healthcare markets in Bulgaria and Europe. With our participation at few independent contract research companies we perform clinical trials in human and apply the highest ethical and scientific standard.

Our mission is to

Enable business success in the life sciences in Bulgaria

We accomplish this goal through leadership, collaboration, innovation and advocacy. As an effort to strengthen cross-border collaboration in the life sciences we expand our relations with companies all over Europe.

Like most innovative capital investments, the clinical and life sciences are inherently risky. In today’s uncertain economic climate, many investors are opting to sit out and wait for more certainty in the market before they invest. Nevertheless, the clinical and life sciences market is an area that healthcare-oriented investors may consider targeting more frequently based on recent results. As the worldwide population ages and more people enter their years of greatest healthcare need, demand for new pharmaceuticals, diagnostics, and medical devices has the potential to go higher than we’ve ever seen. That’s why the need for venture capital is greater and one of the ways to generate cash is the partnerships and licensing agreements with larger companies looking to expand their product pipelines.

Paralax Life Sciences is focused on helping its customers cultivate business growth in the global clinic & life science marketplace through the development, marketing and distribution of high quality solutions. We offer an experienced leadership team and a dynamic and diverse portfolio to demonstrate our customers’ success.

Our mission is to provide a comprehensive range of integrated development services of superior value for our customers, enhancing the regulatory acceptance, the speed to market and the return on investment of their products. We work to improve public health and well-being and our core values are:

• Customer focus
• Demand of total quality
• Value for the individual
• Shareholder value
• Integrity at all levels of execution

Paralax Life Sciences approach focuses on the risk and return characteristics of an investment rather than those criteria that are often used to define venture investments (e.g. sector, therapeutic area, stage of asset development). Hence, we invest in both early stage and late stage companies, platforms and products, discovery and development. However, our main competence are start-ups.

Many factors contribute to the investment attractions of clinic & life science companies:

• There is a considerable unsatisfied demand for healthcare products, driven by increasing consumer expectations and demand for life-style therapeutics.
• The population is ageing, driving up healthcare expenditure per capita.
• There is a lack of safe, effective treatments for many diseases. Furthermore, for some well-tested therapies, treatment rates are low.
• Healthcare costs are increasingly of concern to payers. Innovation in healthcare is the best hope for improving productivity of healthcare delivery.

When it comes to life science productivity, Europe has four of the five top ranked countries in this area. Europe is also a major centre for pharmaceutical development and is home to four of the world’s top five pharmaceutical companies. Successful companies can be built upon Europe’s research base to generate attractive returns for investors. Clinic and life science technologies are global businesses. Regardless of location, companies must strive to attain the standards of, and be benchmarked against, the best competition globally.